Loading
A phase 2 trial of Datopotamab deruxtecan, Capecitabine, Fluorouracil in endometrial cancer and prostate cancer, run by AstraZeneca, now recruiting.
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03). ClinicalTrials.gov record last updated 2026-09-23: recruiting. Enrollment is planned at 454 participants. Primary completion is estimated at 2027-10-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin. Registered primary measures: Objective response rate (ORR); The number of subjects with adverse events/serious adverse events; PSA50 response (Substudy 3 only).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rilvegostomig, Datopotamab deruxtecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads).
Shares Rilvegostomig, Datopotamab deruxtecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads).
Shares Datopotamab deruxtecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Datopotamab deruxtecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Rilvegostomig, Topoisomerase-I inhibitors (and ADC payloads), Endometrial cancer, AstraZeneca.
Shares Datopotamab deruxtecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Datopotamab deruxtecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Carboplatin.
Shares Datopotamab deruxtecan, AstraZeneca, Carboplatin, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/